Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry
-
Published:2024-12
Issue:
Volume:78
Page:103789
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Ladoire SylvainORCID,
Mamguem Kamga Ariane,
Galland Loick,
Desmoulins Isabelle,
Mayeur Didier,
Kaderbhai Courèche,
Ilie Silvia Mihaelia,
Hennequin Audrey,
Jankowski Clementine,
Albuisson Juliette,
Nambot Sophie,
Coutant Charles,
Arnould Laurent,
Reda Manon,
Truntzer Caroline,
Dabakuyo Sandrine
Reference22 articles.
1. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer;Tutt;N Engl J Med,2021
2. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer;Geyer;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2022
3. Patient-reported outcomes in OlympiA: a phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer;Ganz;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2024
4. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial;Johnston;Lancet Oncol,2023
5. ESMO guidance for reporting oncology real-world evidence (GROW);Castelo-Branco;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2023